New breakthrough in Covid-19 treatment: Oral COVID-19 drug Shionogi
Japanese drug manufacturer Shionogi & Co has recently successfully produced oral treatment for Covid-19 Xocova. Accordingly, this is the pioneering line of Covid-19 treatment products in oral form, not vaccination. The Japanese Ministry of Health in Tokyo has also evaluated the effects of this new drug to put it into use for the entire population.
Oral medication for COVID-19 Shionogi & Co
It is known that this is the third antiviral oral tablet product in the world approved to treat patients with Covid-19 in Japan. Before that were two other oral drugs developed by Pfizer and Merck.
According to information from the Vietnam News Agency in Japan, Shionogi has sampled the variant of Omicron from national infectious diseases hospitals for research and drug preparation. And Shionogi has successfully created an oral drug that is effective with Omicron.
Previously, this famous drug company also confirmed that it had prepared a drug to treat Covid-19 for two variants Alpha and Delta.
In the near future, the Osaka-based Shionogi & Co pharmaceutical company will apply to the Japanese Ministry of Health, Labor and Welfare for a marketing license for this drug.
This helps the fight against the Covid-19 epidemic in Japan in particular and around the world in general take a big step forward.
Oral medication for COVID-19 Shionogi & Co
Uses and groups of patients who can use Xocova
Xocova oral medication is reserved for patients infected with Covid-19 who have mild symptoms and must meet the age criteria of 12 years or older. This dose is indicated for 5 to 7 days.
This is also the first time that the Japanese government has given emergency approval for the drug to be used nationwide. In May 2022, this oral drug to treat Covid-19 was approved for use.
Shionogi & Co's Covid treatment pill will be for people with early COVID-19 infection. With the aim of preventing further complications of the patient, significantly reducing the symptoms of cough and high fever.
The prescribed dose is taken once a day to block the function of an enzyme called protease, which slows the spread of the virus in the body.
Japan's Minister of Health, Labor and Welfare Katsunobu Kato announced the decision on the Xocova (Ensitrelvir Fumaric Acid) oral drug after getting approval from the Ministry of Health.
Katsunobu Kato said: "I hope Xocova medicine will contribute to the prevention of SARS-CoV-2 virus as another treatment option." But he also said that Xocova has a few indications that can not be used for pregnant women, children, …
Uses and groups of patients who can use Xocova
Xocova oral drug has been approved and the number of people with covid-19 in Japan increased rapidly
According to exact information from Japan's Kyodo News, since the decision to use Xocova oral medicine, the number of people infected with Covid-19 in this country has increased a lot. The whole country has more than 125,000 people infected in just one day, November 25, and the total number of deaths is 178 people.
These infections are mainly concentrated in major cities such as Tokyo with 12,758 infections, while Hokkaido, Iwate and Yamagata prefectures in northeastern Japan. This is also the record level infection that Japan has recorded since the outbreak of Covid-19 up to now.
Faced with that situation, the Drugs and Medical Devices agency said it had "obtained sufficient information to believe that the drug is effective" from the results of the final phase of clinical trials submitted by Shionogi that helps to speed up time distributing Xocova medicine to users all over the country.
Xocova oral drug was approved and the number of people with covid-19 in Japan increased rapidly
According to the exact statement of Shionogi CEO, Isao Teshirogi, Shionogi can provide this wonderful medicine to more than 1 millions of patients with Covid-19 by the end of March. Further tests for each new sample will take place in Japan, Korea and Vietnam and give the drug amount as treatment for 10 millions of people in April.